Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
Emma Guttman‐Yassky(Icahn School of Medicine at Mount Sinai), Alan D. Irvine(Trinity College Dublin), Amy S. Paller(Northwestern University), Henrique D. Teixeira(AbbVie (United States)), Norito Katoh(Kyoto Prefectural University of Medicine), Brian Calimlim(AbbVie (United States)), Aileen L. Pangan(AbbVie (United States)), Chia‐Yu Chu(National Taiwan University Hospital), Andrew Blauvelt(Veterans Health Administration), Diamant Thaçi(University of Lübeck), Yang Yang(AbbVie (United States)), Meng Liu(AbbVie (United States)), Xiaofei Hu(AbbVie (United States)), John Liu(AbbVie (United States)), Alvina D. Chu(AbbVie (United States)), Hyuck-Ki Hong(University of British Columbia), Allan R. Tenorio(AbbVie (United States)), Kim Papp(University of Toronto), Yihua Gu(Meizhou City People's Hospital), Eric L. Simpson(Oregon Health & Science University)
Cited by 538
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2013|1.3k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2014|1.2k
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
|Journal of the American Academy of Dermatology|2019|917